SRT Therapy vs Mohs Surgery

For a long time, patients suffering from non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma only had one option to turn to for successful treatment. Mohs surgery, developed by general surgeon Frederik E. Mohs in 1938, involves removing one thin layer of tissue from the afflicted area at a time and […]

SRT-100 Vision featured on San Antonio News

SRT-100 Vision a New Technology Revolutionizing Skin Cancer Treatment Skin cancer—it’s the most common cancer in the United States. An estimated one in five Americans will develop skin cancer in their lifetimes, but there’s a new technology that’s revolutionizing how patients are treated and it’s in the San Antonio area. “I’ve had skin cancers now […]

Superficial radiation therapy provides safe, aesthetic results for non-melanoma skin cancer patients

MIAMI — At South Beach Symposium 2017, symposium chairman Mark S. Nestor, MD, PhD, discusses the efficacy and cosmetic benefits of superficial radiation therapy to treat both non-melanoma skin cancer and recurring keloid scars. Nestor presented at the symposium on innovative breakthroughs in superficial radiation therapy, including new technology from Sensus Healthcare. To watch the […]

Sensus Healthcare to Participate in 2017 South Beach Symposium on February 9 – 12 in Miami

— Joe Sardano, Sensus Healthcare CEO, to Participate in CEO Forum on February 11 — Sensus Healthcare Medical Advisory Board Members to Host SRT Workshops on February 9 BOCA RATON, Fla., Feb. 7, 2017 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin […]

Sensus Healthcare to Announce Fourth Quarter and Full Year 2016 Results on February 2, 2017

BOCA RATON, Fla., Jan. 19, 2017 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today announced that it will report its fourth quarter and full year 2016 financial results on Thursday, February 2, 2017 […]

Sensus Healthcare to Participate in Annual JP Morgan Healthcare Conference Week on January 9th – 11th in San Francisco

BOCA RATON, Fla., Jan. 3, 2017 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers (NMSC) and other skin conditions such as keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, CEO and Arthur Levine, CFO will participate in the Annual JP Morgan Healthcare […]

Do You Have a Keloid Scar?

If you have a scar that doesn’t seem to be fading, or even appears to be growing in size, it is important to determine whether that scar is a keloid or not. There are two types of raised scars: keloid and hypertrophic. While both hypertrophic scars and keloid scars themselves are benign, the uncontrolled growth […]

Sensus Healthcare to Participate in Two Upcoming Investor Conferences on November 30th and December 1st

— Evercore ISI MedTools Investor Conference in Boston, MA — Drexel Hamilton’s Emerging Growth Conference in New York, NY BOCA RATON, Fla., Nov. 16, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), […]

Sensus Healthcare Reports Third Quarter 2016 Results

– Q3 revenues increased 58% year-over-year to $3.33 million – Worldwide installed base increased to 256 units BOCA RATON, Fla., Nov. 3, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today reported […]

Patients Benefit from Non-Surgical SRT

If you’ve been diagnosed with non-melanoma skin cancer, such as basal cell carcinoma or squamous cell carcinoma, you now have a new, non-surgical option for treatment. Superficial Radio Therapy (SRT) with the SRT-100™ delivers a precise, calibrated dose of SRT that only goes skin deep. This low-dose of Superficial Radio Therapy safely destroys non-melanoma skin […]

Physicians Prefer SRT Therapy for Treatment of Non-Melanoma Skin Cancer and Keloid Scars

Eighteen million people are affected by unsightly and sometimes painful keloid scars, and many of them go through life believing treatment for this embarrassing condition is next to impossible, if possible at all. You can help restore your patient’s confidence and self-esteem by offering keloid treatment with Superficial Radio Therapy (SRT therapy) following surgical removal. […]

Sensus Healthcare to Announce Third Quarter 2016 Results on November 3, 2016

BOCA RATON, Fla., Oct. 20, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today announced that it will report its third quarter 2016 financial results on Thursday, November 3, 2016 after the market […]

Sensus Healthcare to Participate in Important Dermatological and Institutional Investor Conferences from October 20th to October 23rd

–2016 Fall Clinical Dermatology Conference in Las Vegas, NV –Dawson James 2016 Small Cap Growth Stock Conference in Jupiter, FL BOCA RATON, Fla., Oct. 6, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy […]